Diagnostic significance of MRI versus CT using identical PET data in patients with recurrent differentiated thyroid cancer: A PET/MRI study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
21 Apr 2023
21 Apr 2023
Historique:
medline:
25
4
2023
pubmed:
21
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
In this retrospective study we compared magnet resonance imaging (MRI) and computed tomography (CT) each combined with identical 2-deoxy-2-[18F] fluoro-D-glucose or 2-[18F] F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) data in patients with recurrent differentiated thyroid cancer (DTC). In total 42 patients with DTC were examined. All patients underwent FDG PET/MRI and CT, the latter originating from one of the following examinations: I-131 single photon emission computed tomography/CT (32/42), low dose FDG PET/CT (5/42) or diagnostic FDG PET/CT (5/42). Two readers assessed FDG PET/MRI as well as FDG PET/CT, with the latter CT coming from one of the above examinations performed at a maximum temporal interval of 5 days from PET/MRI. Local recurrence, cervical lymph node - and pulmonary metastases were assessed in a consensus read. Lesions rated with a high malignancy score (score 4 or 5) were further analyzed. Every malignant lesion was verified if it was identified by one of both or by both modalities. In 20 of 42 patients altogether 100 malignant lesions were present. In 11/20 patients in total 15 local recurrences (15 in MRI/ 9 in CT: 9 CT/MRI, 6 MRI only, 0 CT only; P = .04) were found with a statistically significant better performance of MRI. Regarding lymph node metastases, in total 13 lesions (12 in MRI/ 8 in CT: 7 CT/MRI, 5 MRI only, 1 CT only; P = .22) in 8/20 patients were found with no significant difference between both modalities. Furthermore, in 9/20 patients in total 72 lung lesions (40 in MRI/ 63 in CT: 31 CT/MRI, 9 MRI only, 32 CT only; P = .001) were found with a statistically significant better performance of CT. In 33/42 patients follow up was available and supported the observations. In patients with recurrent DTC, PET/MRI showed superiority compared to PET/CT in evaluation of the neck region. PET/MRI was inferior to PET/CT in evaluation of the lung. PET/MRI in combination with a low dose CT of the lung may thus represent the ideal staging tool in patients with recurrent DTC.
Identifiants
pubmed: 37083773
doi: 10.1097/MD.0000000000033533
pii: 00005792-202304210-00012
pmc: PMC10118350
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Iodine-131
0
Iodine Radioisotopes
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e33533Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Sanabria A, Kowalski LP, Shah JP, et al. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis. Head Neck. 2018;40:855–66.
Dionigi G, Fama’ F, Pignata SA, et al. Usefulness of PET-CT scan in recurrent thyroid cancer. World J Otorhinolaryngol Head Neck Surg. 2020;6:182–7.
Liu H, Wang X, Yang R, et al. Recent development of nuclear molecular imaging in thyroid cancer. Biomed Res Int [Internet]. 2018;2018:2149532. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987314/ .
Vrachimis A, Burg MC, Wenning C, et al. [(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:212–20.
Hempel JM, Kloeckner R, Krick S, et al. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer. Cancer Imaging. [Internet]. 2016;16:37. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093960/ .
Feine U, Lietzenmayer R, Hanke JP, et al. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. Nuklearmedizin. 1995;34:127–34.
Fallahi P, Mazzi V, Vita R, et al. New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci. 2015;16:6153–82.
Lee JW, Lee SM, Lee DH, et al. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med. 2013;54:1230–6.
White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin Drug Discov. 2015;10:427–39.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer. Horm Metab Res. 2020;52:562–77.
Bonjoc KJ, Young H, Warner S, et al. Thyroid cancer diagnosis in the era of precision imaging. J Thorac Dis. 2020;12:5128–39.
Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. [Internet]. 2018;91:20180136. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475953/ .
Riemann B, Uhrhan K, Dietlein M, et al. Diagnostic value and therapeutic impact of (18) F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study. Nuklearmedizin . 2013;52:1–6.
Khan N, Oriuchi N, Higuchi T, et al. PET in the follow-up of differentiated thyroid cancer. Br J Radiol. 2003;76:690–5.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
Eiber M, Takei T, Souvatzoglou M, et al. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med. 2014;55:191–7.
Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845–55.
Balyasnikova S, Löfgren J, de Nijs R, et al. PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. Am J Nucl Med Mol Imaging. 2012;2:458–74.
Nagarajah J, Jentzen W, Hartung V, et al. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging. 2011;38:1862–8.
Hoang JK, Branstetter BF, Gafton AR, et al. Imaging of thyroid carcinoma with CT and MRI: approaches to common scenarios. Cancer Imaging. 2013;13:128–39.
Schmidbauer B, Menhart K, Hellwig D, et al. Differentiated thyroid cancer–treatment: state of the art. Int J Mol Sci. [Internet]. 2017;18:1292. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486113/ .
Verburg FA, Mäder U, Tanase K, et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab. 2013;98:172–80.
Rauscher I, Eiber M, Fürst S, et al. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. J Nucl Med Off Publ Soc Nucl Med. 2014;55:724–9.
Chandarana H, Heacock L, Rakheja R, et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology. 2013;268:874–81.
Ishii S, Shimao D, Hara T, et al. Comparison of integrated whole-body PET/MR and PET/CT: is PET/MR alternative to PET/CT in routine clinical oncology? Ann Nucl Med. 2016;30:225–33.
Torigian DA, Zaidi H, Kwee TC, et al. PET/MR imaging: technical aspects and potential clinical applications. Radiology. 2013;267:26–44.
Eiber M, Martinez-Möller A, Souvatzoglou M, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38:1691–701.
Som PM, Curtin HD, Mancuso AA. Imaging-based nodal classification for evaluation of neck metastatic adenopathy. AJR Am J Roentgenol. 2000;174:837–44.
Klain M, Nappi C, Nicolai E, et al. Comparison of simultaneous 18F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2020;47:3066–73.
Queiroz MA, Hüllner M, Kuhn F, et al. PET/MRI and PET/CT in follow-up of head and neck cancer patients. Eur J Nucl Med Mol Imaging. 2014;41:1066–75.
Loeffelbein DJ, Souvatzoglou M, Wankerl V, et al. Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer. BMC Cancer. 2014;14:846.